Shots:
- China’s NMPA has accepted IND application for RN1871 for hypertension, with Rona planning to advance it in P-I trial to assess its safety, PK, & preliminary efficacy in humans
- Preclinical studies have demonstrated AGT suppression & sustained blood pressure control, with reduced dosing frequency of RN1871
- RN1871 is engineered to suppress AGT mRNA expression in the liver, blocking the production of the key precursor protein involved in the Renin-Angiotensin-Aldosterone System (RAAS)
Ref: Prnewswire | Image: Rona Therapeutics
Related News:- HighField Biopharmaceuticals Seeks NMPA’s IND Clearance for HF158K1 & HFK2 to Treat Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
